SynBiotic SE

News

27.09.2024 11:19:23
EQS-News: Share price target 12.50 euros: Annual General Meeting supports SYNBIOTIC's growth plans with over 99 percent approval
17.09.2024 09:01:14
Original-Research: SynBiotic SE (von NuWays AG): BUY
16.08.2024 12:30:07
EQS-News: SYNBIOTIC Annual General Meeting on 20.09.2024: Increasing sales drive growth
23.05.2024 10:31:25
EQS-News: Berlin, Prague, Berlin: SYNBIOTIC and CEO Daniel Kruse on roadshow
08.05.2024 14:27:26
EQS-News: Acquisition of WEECO Pharma: SYNBIOTIC significantly expands its position in the medical cannabis market
25.04.2024 12:33:59
EQS-News: 1.6 million euros for Hanf Farm: Federal Ministry for Economic Affairs and Climate Protection funds bio-economy project
23.04.2024 10:33:37
EQS-News: SYNBIOTIC acquires Ilesol: Enormous competitive advantages through cannabinoid extracts and isolates from own production
19.03.2024 13:22:12
EQS-DD: SynBiotic SE: Frank Otto, Granting of 86,465 subscription rights as part of the rights issue of a 6% convertible bond March 2024/2025.
15.03.2024 18:01:11
EQS-DD: SynBiotic SE: Frank Otto, Granting of 86,465 subscription rights as part of the rights issue of a 6% convertible bond March 2024/2025.
14.03.2024 14:08:12
EQS-DD: SynBiotic SE: HempConsult GmbH, Granting of 422,100 subscription rights as part of the issue of a convertible bond.

Downloads

Latest Research
Initiation

Analyst

Christian Sandherr

Equity Research

MailLinkedIn

Latest Research

Christian Sandherr

17 Sep 24

SynBiotic transformation: Reaching new operational high(t)s

Initiation
Christian Sandherr

29 Aug 23

Gearing up to capitalize on favorable market dynamics; chg.

Update
Christian Sandherr

28 Dec 22

Strategic realignment to capitalize on cannabis legalization; chg.

Update

Best-in-class research on selected German and European small caps. Immediately at publication and 100% free of charge.

To learn how we process your data, visit our Privacy Notice.